LCP-Tacro vs. Azathioprine for the Treatment of Autoimmune Hepatitis

This study has been completed.
Sponsor:
Information provided by:
Veloxis Pharmaceuticals
ClinicalTrials.gov Identifier:
NCT00608894
First received: January 23, 2008
Last updated: October 21, 2009
Last verified: October 2009
  Purpose

An open-label, multi-center, prospective, randomized study to evaluate the efficacy, safety and tolerability of LCP-Tacro tablets given once daily vs. azathioprine, each in combination with prednisone, for the treatment of autoimmune hepatitis (AIH).


Condition Intervention Phase
Autoimmune Hepatitis
Drug: LCP-Tacro (tacrolimus)
Drug: Azathioprine
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Phase II, Open-Label, Multi-Center, Prospective, Randomized Study of LCP-Tacro Tablets vs. Azathioprine, in Combination With Corticosteroids, for the Treatment of Autoimmune Hepatitis

Resource links provided by NLM:


Further study details as provided by Veloxis Pharmaceuticals:

Primary Outcome Measures:
  • Percent of patients that achieve biochemical remission of (AIH) at Month 6 during treatment with LCP-Tacro + prednisone or azathioprine + prednisone. Biochemical remission is defined as ALT, total bilirubin and gamma globulin within normal limits. [ Time Frame: 6 months ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Percent of patients who achieve biochemical remission by Month 3 during treatment with LCP-Tacro + prednisone or azathioprine + prednisone. [ Time Frame: 3 months ] [ Designated as safety issue: No ]
  • Percents of patients in each treatment group classified as either in remission, having an incomplete response, a treatment failure, or a case of relapse. Each patient will be classified as being one of the four states at Month 6. [ Time Frame: 6 months ] [ Designated as safety issue: No ]

Estimated Enrollment: 60
Study Start Date: December 2007
Study Completion Date: July 2009
Primary Completion Date: February 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: LCP-Tacro
LCP-Tacro tablets(1,2,and 5mg tacrolimus)+ prednisone tablets(5mg)
Drug: LCP-Tacro (tacrolimus)
LCP-Tacro(tacrolimus)tablets starting at 2 mg once daily, then adjusted to achieve and maintain target whole blood tacrolimus levels of 3 - 6 ng/mL, plus prednisone 30 mg/day for one week, then 20 mg/day for one week, then 15 mg/day for two weeks, then 10 mg/day through Month 6.
Other Name: 1,2,and 5mg tacrolimus tablets
Active Comparator: Azathioprine
Azathioprine tablets(50mg)+ prednisone tablets(5mg)
Drug: Azathioprine
Azathioprine tablets 50 - 100 mg (approximately 1 mg/kg) once daily, plus prednisone 30 mg/day for one week, then 20 mg/day for one week, then 15 mg/day for two weeks, then 10 mg/day through Month 6.
Other Name: 50mg azathioprine tablets + 5mg prednisone tablets

Detailed Description:

An open-label, multi-center, prospective, randomized study to evaluate the efficacy, safety and tolerability of LCP-Tacro tablets given once daily vs. azathioprine for the treatment of autoimmune hepatitis (AIH).

Patients with histologically confirmed chronic hepatitis who fulfill criteria established by the International Autoimmune Hepatitis Group (IAIHG) and Inclusion and Exclusion criteria will be enrolled after having signed an informed consent document.

Up to 60 patients will be randomized (1:1) to receive treatment with LCP-Tacro + prednisone vs. azathioprine (AZA) + prednisone.

  • LCP-Tacro will be started at 2 mg once daily (q.d.) with weekly measurement of tacrolimus whole blood trough levels and adjustment of the daily dose of LCP-Tacro to achieve target tacrolimus levels of 3 - 6 ng/mL. Patients with histological evidence of cirrhosis and a Model for End-Stage Liver Disease (MELD) score ≤ 8 will commence LCP-Tacro at a fixed dose of 1 mg once daily, with subsequent dosage adjustments to maintain tacrolimus trough levels at 3 - 6 ng/mL.
  • AZA will be started at 50 - 100 mg (approximately 1 mg/kg) once daily (q.d.).

Patients will also commence treatment with prednisone 30 mg/day for one week, then 20 mg/day for one week, then 15 mg/day for two weeks, then 10 mg/day through Month 6.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Men and women at least 18 years of age with a diagnosis of definite or probable AIH defined by the revised International Autoimmune Hepatitis Group (IAIHG) criteria
  • Elevation of serum ALT ≥ 1.5 times the upper limit of normal
  • Liver biopsy showing chronic hepatitis consistent with AIH
  • Patients able to swallow the study medication
  • Patients capable of understanding the purposes and risks of the study, who can give written informed consent and who are willing to participate in and comply with the study
  • Women of childbearing potential must have a negative serum pregnancy test within seven days prior to receiving study medication and agree to use contraceptive measures to avoid pregnancy during participation in the trial.

Exclusion Criteria:

  • Patients with other concurrent liver disease
  • Patients with cirrhosis on liver biopsy with a MELD score > 15
  • Patients with a history or presence of decompensated liver disease
  • Patients with serum creatinine ≥ 1.5 mg/dL prior to enrollment
  • Patients positive for HCV RNA or Hepatitis B surface antigen (HBsAg)
  • Patients with a history of alcohol intake > 25 g/day within the past six months
  • Patients with TSH outside normal range accompanied by an abnormal T4
  • Patients with alpha-fetoprotein ≥ 20 ng/mL
  • Patients with severe anemia (hemoglobin < 8 g/dL), leukopenia (WBC < 4000/mm3), or thrombocytopenia (platelet count < 100,000/mm3)
  • Patients with a history of recent exposure to hepatotoxic drugs
  • Patients who require therapy with any immunosuppressive agent other than those prescribed in the study
  • Patients unable or unwilling to provide informed consent
  • Pregnant or nursing women
  • Patients with reproductive potential who are unwilling/unable to use a double barrier method of contraception
  • Patients who have been treated with another investigational agent in the three months prior to enrollment
  • Patients receiving any drug interfering with tacrolimus metabolism
  • Patients with current malignancy or a history of malignancy (within the past 5 years), except basal or non-metastatic squamous cell carcinoma of the skin that has been treated successfully
  • Patients with uncontrolled concomitant infection, a systemic infection requiring treatment, or any other unstable medical condition that could interfere with the study objectives
  • Patients with severe diarrhea, vomiting, active peptic ulcer or gastrointestinal disorder that may affect the absorption of tacrolimus
  • Patients with a known hypersensitivity to azathioprine, corticosteroids or tacrolimus
  • Patients with any form of current substance abuse, psychiatric disorder or a condition that, in the opinion of the Investigator, may invalidate communication with the Investigator
  • Patients who are recipients of an organ transplant or who require treatment with immunosuppressives or corticosteroids for any disease other than AIH.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00608894

Locations
United States, Arizona
Mayo Clinic - Phoenix
Phoenix, Arizona, United States, 85054
United States, Florida
Mayo Clinic - Jacksonville
Jacksonville, Florida, United States, 32216
United States, Illinois
Northwestern University
Chicago, Illinois, United States, 60611
United States, Minnesota
University of Minnesota
Minneapolis, Minnesota, United States, 55455
Mayo Clinic
Rochester, Minnesota, United States, 55905
United States, New York
Mount Sinai Medical Center
New York, New York, United States, 10029
United States, Texas
St. Luke's Advanced Liver Therapies
Houston, Texas, United States, 77030
United States, Virginia
Virginia Commonwealth University
Richmond, Virginia, United States, 23298
Canada, Alberta
Heritage Medical Research Clinic
Calgary, Alberta, Canada, T2N 4N1
Zeildler Ledcor Centre
Edmonton, Alberta, Canada, T6G 2X8
Canada, Manitoba
John Buhler Research Centre, University of Manitoba Health Sciences Centre
Winnipeg, Manitoba, Canada, R3E 3P4
Canada, Nova Scotia
Queen Elizabeth II Health Sciences Centre
Halifax, Nova Scotia, Canada, B3H 2Y9
Sponsors and Collaborators
Veloxis Pharmaceuticals
Investigators
Principal Investigator: Gerald Y Minuk, M.D. University of Manitoba Health Sciences Centre, Winnipeg
Principal Investigator: Andrew Mason, MD University of Alberta, Edmonton
Principal Investigator: Russell H Wiesner, MD Mayo Clinic - Rochester, MN
Principal Investigator: John M Vierling, MD Baylor College of Medicine
Principal Investigator: Velimir A Luketic, MD Virginia Commonwealth University, Richmond, VA
Principal Investigator: Joseph A Odin, MD, PhD Mount Sinai Medical Center, New York, NY
Principal Investigator: Elizabeth Carey, MD Mayo Clinic - Phoenix
Principal Investigator: John R Lake, MD University of Minnesota - Clinical and Translational Science Institute
Principal Investigator: Barry G Rosser, MD Mayo Clinic
Principal Investigator: Steven L Flamm, MD Northwestern University
Principal Investigator: Kevork M Peltekian, MD Queen Elizabeth II Health Sciences Centre
Principal Investigator: Mark G Swain, MD University of Calgary
  More Information

No publications provided

Responsible Party: H. Eugene Griffin, MS, DVM, LifeCycle Pharma A/S
ClinicalTrials.gov Identifier: NCT00608894     History of Changes
Other Study ID Numbers: LCP-Tacro Study 2016
Study First Received: January 23, 2008
Last Updated: October 21, 2009
Health Authority: United States: Food and Drug Administration
Canada: Health Canada

Keywords provided by Veloxis Pharmaceuticals:
Autoimmune hepatitis
Chronic active hepatitis

Additional relevant MeSH terms:
Hepatitis, Autoimmune
Hepatitis
Hepatitis A
Liver Diseases
Digestive System Diseases
Hepatitis, Viral, Human
Virus Diseases
Enterovirus Infections
Picornaviridae Infections
RNA Virus Infections
Hepatitis, Chronic
Autoimmune Diseases
Immune System Diseases
Azathioprine
Tacrolimus
Prednisone
Antimetabolites
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Antimetabolites, Antineoplastic
Antineoplastic Agents
Therapeutic Uses
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Antirheumatic Agents
Glucocorticoids
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists
Antineoplastic Agents, Hormonal

ClinicalTrials.gov processed this record on July 20, 2014